who's who

3 Houston innovators to know this week

This week's Houston innovators to know include Travis Parigi of LiquidFrameworks, Kathy Luders of NASA, and Stephen Spann of the University of Houston. Photos courtesy

Starting a new week, we'd like to introduce you to three Houston innovators who have recently made headlines. All three represent industries at the core of Houston's business community — from space and energy to health care.

Travis Parigi, founder and CEO of LiquidFrameworks

Travis Parigi, founder and CEO of LiquidFrameworks, joins the Houston Innovators Podcast to discuss how he's navigating both a global pandemic and an oil downturn. Photo courtesy of LiquidFrameworks

Travis Parigi, founder and CEO of LiquidFrameworks, joined the Houston Innovators Podcast to discuss how both the oil downturn and the pandemic has affected his business, which provides cloud-based, mobile field operations management solutions to oil and gas, environmental, and industrial service companies.

"We've seen these types of challenges in the past within the oil and gas space — it is cyclical based on commodities," Parigi explains on thi week's episode of the Houston Innovators Podcast. "We're well positioned to weather these storms."

Parigi shares his biggest concerns about the oil and gas market and how he's looking into partnering with another Houston energy tech startup, Data Gumbo, on the episode. Listen and read more.

Kathy Lueders, associate administrator of the Human Exploration and Operations Mission Directorate at NASA's Johnson Space Center

Kathy Lueders will lead the future of human space flight at NASA. Photo via nasa.gov

NASA's Johnson Space Center, home to human exploration, has a new leader. Kathy Lueders, formerly the commercial crew program manager, has been named associate administrator of the Human Exploration and Operations (HEO) Mission Directorate by NASA Administrator Jim Bridenstine on Friday, June 12.

"Kathy gives us the extraordinary experience and passion we need to continue to move forward with Artemis and our goal of landing the first woman and the next man on the Moon by 2024," says Bridenstine in a news release. "She has a deep interest in developing commercial markets in space, dating back to her initial work on the space shuttle program."

Lueders has been with NASA for over 12 years — spending time at both JSC and Kennedy Space Center in Florida. Read more.

Dr. Stephen Spann, founding dean of the University of Houston's College of Medicine

The University of Houston broke ground on its new medical school building and named the College of Medicine's inaugural class. Photo via UH.edu

The University of Houston is the first institution in town in about 50 years to establish a new medical school, and UH is doing it for a specific reason — to get more primary care doctors in practice. UH's College of Medicine plans to have 50 percent of graduates choose primary care specialties including family medicine, general internal medicine, and general pediatrics. For some perspective, nationally, only about 20 percent of medical students choose primary care.

"We were very deliberate in our pursuit of medical students who fit the mission. This is much different than most other medical schools because we need different solutions for the current health care problems facing our city and state," said Dr. Stephen Spann, founding dean of the College of Medicine, in a statement. Read more.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News